Biomarkers of PARP inhibitor sensitivity

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

(2010) A. A. Rodriguez et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

(2010) Sherry X. Yang et al.   CANCER BIOLOGY & THERAPY

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

(2010) P. Gottipati et al.   CANCER RESEARCH

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

(2010) Britta Weigelt et al.   LANCET ONCOLOGY

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

(2009) T Zaremba et al.   BRITISH JOURNAL OF CANCER

High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer

(2009) H. Holstege et al.   CANCER RESEARCH

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability

(2009) David Schild et al.   NUCLEIC ACIDS RESEARCH

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

A Mutant Allele of MRE11 Found in Mismatch Repair-deficient Tumor Cells Suppresses the Cellular Response to DNA Replication Fork Stress in a Dominant Negative Manner

(2008) Qin Wen et al.   MOLECULAR BIOLOGY OF THE CELL

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility

(2008) C. Godon et al.   NUCLEIC ACIDS RESEARCH